BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• Press Releases

  Cardiff Oncology Announces $10 Million Registered Direct Offering

  July 15, 2026

   · 

  6 min read
• Press Releases

  Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

  July 15, 2026

   · 

  3 min read
• Press Releases

  Valitor to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

  July 15, 2026

   · 

  1 min read
• Press Releases

  Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump

  July 15, 2026

   · 

  4 min read
• Press Releases

  Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies

  July 15, 2026

   · 

  10 min read
• 

  Alzheimer’s disease

  AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance

  Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. However, at the Alzheimer’s Association International Conference on Wednesday, Lilly revealed it is studying the potential of maintenance therapy for patients who need it.

  July 15, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

  New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly.

  July 15, 2026

   · 

  6 min read

   · 

  Heather McKenzie
• Press Releases

  Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

  July 15, 2026

   · 

  9 min read
• Press Releases

  Attovia Therapeutics Appoints John W. Smither to Board of Directors

  July 15, 2026

   · 

  5 min read
• Press Releases

  Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026

  July 15, 2026

   · 

  6 min read